Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0435-7. [Epub ahead of print]

PMID:
30858549
2.

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.

Dhakal B, Pagenkopf A, Umair Mushtaq M, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F.

Leuk Lymphoma. 2019 Mar 8:1-5. doi: 10.1080/10428194.2019.1585836. [Epub ahead of print] No abstract available.

PMID:
30845856
3.

Granulocyte colony-stimulating factor utilization postautologous hematopoietic stem cell transplant in multiple myeloma patients: Does one size fit all?

Jackson ER, Jared JR, Piccolo JK, Woo KM, Mably MS, Reed MP, Callander NS.

J Oncol Pharm Pract. 2018 Jan 1:1078155218781888. doi: 10.1177/1078155218781888. [Epub ahead of print]

PMID:
29890920
4.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
5.

Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.

Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S.

J Biol Chem. 2018 Feb 16;293(7):2452-2465. doi: 10.1074/jbc.RA117.000667. Epub 2017 Dec 26.

6.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.

Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e61-e67. doi: 10.1016/j.clml.2017.10.006. Epub 2017 Nov 4.

7.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332. Erratum in: Lancet Haematol. 2018 Dec;5(12):e608.

8.

Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.

Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F.

J Immunol. 2017 Sep 1;199(5):1933-1941. doi: 10.4049/jimmunol.1700529. Epub 2017 Jul 28.

9.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
10.

Utilization and evaluation of noncore chemotherapy regimens within an academic medical center.

Jared JR, Mably MS, Makielski R, Reed MP, Fallon MJ, Liu G, Mulkerin D, Callander NS.

J Oncol Pharm Pract. 2017 Oct;23(7):518-524. doi: 10.1177/1078155216657679. Epub 2016 Jul 6.

PMID:
27388159
11.

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series.

Jurczyszyn A, Olszewska-Szopa M, Vesole AS, Vesole DH, Siegel DS, Richardson PG, Paba-Prada C, Callander NS, Huras H, Skotnicki AB.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):e39-45. doi: 10.1016/j.clml.2015.11.020. Epub 2015 Dec 2. Review.

PMID:
26847816
12.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.

13.

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.

Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV.

Blood. 2015 Sep 10;126(11):1294-301. doi: 10.1182/blood-2014-12-613927. Epub 2015 Jul 8.

14.

Single-molecule analysis reveals widespread structural variation in multiple myeloma.

Gupta A, Place M, Goldstein S, Sarkar D, Zhou S, Potamousis K, Kim J, Flanagan C, Li Y, Newton MA, Callander NS, Hematti P, Bresnick EH, Ma J, Asimakopoulos F, Schwartz DC.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7689-94. doi: 10.1073/pnas.1418577112. Epub 2015 Jun 8.

15.

MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S.

Integr Biol (Camb). 2015 Jun;7(6):643-54. doi: 10.1039/c5ib00071h. Epub 2015 May 22.

16.

Older patients with myeloma derive similar benefit from autologous transplantation.

Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803. doi: 10.1016/j.bbmt.2014.07.013. Epub 2014 Jul 18.

17.

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.

Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P.

Br J Haematol. 2012 Aug;158(3):336-46. doi: 10.1111/j.1365-2141.2012.09154.x. Epub 2012 May 15.

18.

Microscale functional cytomics for studying hematologic cancers.

Young EW, Pak C, Kahl BS, Yang DT, Callander NS, Miyamoto S, Beebe DJ.

Blood. 2012 Mar 8;119(10):e76-85. doi: 10.1182/blood-2011-10-384347. Epub 2012 Jan 18.

19.

Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.

Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Williams ME, Siegel DS, Greipp PR, Rajkumar SV, Fonseca R.

Br J Haematol. 2011 Nov;155(3):340-8. doi: 10.1111/j.1365-2141.2011.08849.x. Epub 2011 Sep 9.

20.

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, Callander NS, Haug JL, Siegel DS, Greipp PR, Fonseca R, Rajkumar SV.

Blood. 2011 Oct 20;118(16):4359-62. doi: 10.1182/blood-2011-03-342089. Epub 2011 Aug 22.

21.

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS.

Br J Haematol. 2011 Oct;155(2):190-7. doi: 10.1111/j.1365-2141.2011.08820.x. Epub 2011 Aug 16.

22.

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.

Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN.

Blood. 2011 Aug 18;118(7):1979-88. doi: 10.1182/blood-2011-02-337329. Epub 2011 Jun 20.

23.

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S.

Mol Cancer. 2010 Jul 6;9:176. doi: 10.1186/1476-4598-9-176.

24.

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group.

Lancet Oncol. 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.

25.

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S.

Mol Cancer Res. 2008 Aug;6(8):1356-64. doi: 10.1158/1541-7786.MCR-08-0108.

26.

Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.

Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL.

Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8. doi: 10.3816/CLM.2008.n.018.

27.

Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.

Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH, Flomenberg N, Selby G, Lemaistre CF.

Biol Blood Marrow Transplant. 2005 Mar;11(3):188-93.

28.

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD.

Exp Hematol. 2005 Mar;33(3):272-8.

PMID:
15730850
29.

Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis.

Pollack MS, Speeg KV, Callander NS, Freytes CO, Espinoza AA, Esterl RM, Abrahamian GA, Washburn WK, Halff GA.

Hum Immunol. 2005 Jan;66(1):28-31.

PMID:
15620459
30.

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.

Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, Alberts DS; Southwest Oncology Group Study.

Gynecol Oncol. 2004 Jul;94(1):98-106.

PMID:
15262126
31.

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.

Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ.

Blood. 2004 Mar 15;103(6):2308-15. Epub 2003 Nov 13.

32.

AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.

Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD.

Blood. 2003 May 15;101(10):3778-83. Epub 2003 Jan 30.

Supplemental Content

Loading ...
Support Center